Equity Profile

TARS

Tarsus Pharmaceuticals, Inc.

Health CarePharmaceuticals$2.6B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Tarsus Pharmaceuticals, Inc. is a healthcare company focused on developing innovative therapies for serious eye diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and performance this quarter.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, crucial for investor confidence.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TARS Q2-2026 Earnings Preview

Context

Company Snapshot

Tarsus Pharmaceuticals, Inc. is a healthcare company focused on developing innovative therapies for serious eye diseases. With a market cap of $3 billion, it operates in the pharmaceuticals sector, which is critical for addressing unmet medical needs and improving patient outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+14.49%

Avg Stock Reaction

-0.37%

Last Quarter Recap

In Q1 2026, Tarsus reported an EPS of -$0.16, outperforming expectations by 64.91%. However, revenue figures were not disclosed, leaving some uncertainty about overall financial health.

Management Promises & Guidance

Focus on advancing clinical trials for their lead product.
Commitment to improving operational efficiency.
Plans to enhance market access for their therapies.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Tarsus's upcoming earnings report, especially given their recent EPS surprises. However, the lack of revenue guidance leaves some uncertainty.

Bull Case

If Tarsus continues to beat EPS expectations and provides positive updates on their product pipeline, it could lead to increased investor confidence and stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides lackluster updates on their pipeline, it could lead to a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for clinical trials and potential product launches?

This information will be crucial for understanding the company's growth prospects and potential revenue streams.

How does Tarsus plan to address market access challenges for its therapies?

Market access is vital for revenue generation, and any challenges could impact the company's financial outlook.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of Tarsus's upcoming product launches, which could significantly boost revenue.

Supporting Evidence

Tarsus has a strong track record of beating EPS estimates, suggesting potential for positive surprises.

Options pricing indicates a high expected move, reflecting uncertainty that could lead to a larger reaction than anticipated.

Key Risk

If the company provides strong updates on clinical trials, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around the company's ability to execute on its product pipeline and achieve market access.

Bull Confirmed If

A clear timeline for upcoming product launches and positive trial results would confirm the bull case.

Bear Confirmed If

Any delays or negative updates regarding clinical trials could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±30.64%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±30.6% while TARS has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

43.4%

Calls (300)P/C Ratio: 0.19Puts (500)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tarsus beats expectations and raises guidance, history suggests a potential average move of +2.83% on the day.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may see a muted reaction.

Miss

Should the company miss expectations, history suggests an average move of +2.83%, indicating a potential downside.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timeline for clinical trial results.
2Details on market access strategies for their therapies.
3Any changes in operational efficiency initiatives.
4Insights into competitive positioning within the pharmaceuticals sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Tarsus Pharmaceuticals, Inc. is a healthcare company focused on developing innovative therapies for serious eye diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and performance this quarter.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, crucial for investor confidence.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TARS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+14.49%

Avg Stock Reaction

-0.37%

Last Quarter Recap

In Q1 2026, Tarsus reported an EPS of -$0.16, outperforming expectations by 64.91%. However, revenue figures were not disclosed, leaving some uncertainty about overall financial health.

Management Promises & Guidance

Focus on advancing clinical trials for their lead product.
Commitment to improving operational efficiency.
Plans to enhance market access for their therapies.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Tarsus's upcoming earnings report, especially given their recent EPS surprises. However, the lack of revenue guidance leaves some uncertainty.

Bull Case

If Tarsus continues to beat EPS expectations and provides positive updates on their product pipeline, it could lead to increased investor confidence and stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides lackluster updates on their pipeline, it could lead to a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for clinical trials and potential product launches?

This information will be crucial for understanding the company's growth prospects and potential revenue streams.

How does Tarsus plan to address market access challenges for its therapies?

Market access is vital for revenue generation, and any challenges could impact the company's financial outlook.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of Tarsus's upcoming product launches, which could significantly boost revenue.

Supporting Evidence

Tarsus has a strong track record of beating EPS estimates, suggesting potential for positive surprises.

Options pricing indicates a high expected move, reflecting uncertainty that could lead to a larger reaction than anticipated.

Key Risk

If the company provides strong updates on clinical trials, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around the company's ability to execute on its product pipeline and achieve market access.

Bull Confirmed If

A clear timeline for upcoming product launches and positive trial results would confirm the bull case.

Bear Confirmed If

Any delays or negative updates regarding clinical trials could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±30.64%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±30.6% while TARS has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

43.4%

Calls (300)P/C Ratio: 0.19Puts (500)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tarsus beats expectations and raises guidance, history suggests a potential average move of +2.83% on the day.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may see a muted reaction.

Miss

Should the company miss expectations, history suggests an average move of +2.83%, indicating a potential downside.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timeline for clinical trial results.
2Details on market access strategies for their therapies.
3Any changes in operational efficiency initiatives.
4Insights into competitive positioning within the pharmaceuticals sector.